All In Biotech

Drug Trial Radar · NCT04404049

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

The HIV Functional Cure Potential of UB-421: A Phase II, Randomized, Open-label, Controlled, 48 Week, Proof of Concept Study, to Evaluate the Safety of UB-421 in Combination With Standard Antiretroviral Therapy (ART) and the Efficacy of HIV Reservoir Reduction as Compared With ART Alone in ART Stabilized HIV-1 Patients

Last checked: Nov 19, 2026Latest source record: May 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

39

Planned (sponsor's estimate)

Start

Dec 1, 2023

Primary completion

Jun 30, 2024

Study completion Jun 30, 2025

Sponsor

Sponsor type
Industry
First posted
May 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, randomized, open-label, multi-center, active-controlled study to assess the safety, tolerability, and efficacy of UB-421 administered as an add-on to the standard ART in ART-treated HIV-1 subjects with stably suppressed HIV-1 plasma VL. The study will be conducted at multiple study centers, designated AIDS hospitals in China.

Conditions

  • HIV-1-infection

Interventions

  • UB-421(25 mg/kg) Q2WBiological

    Monoclonal antibody by IV infusion plus standard ART

  • UB-421(25 mg/kg) Q4WBiological

    Monoclonal antibody by IV infusion plus standard ART

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. treatment related TEAEsTime frame: 48Weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.